ACADIA Pharmaceuticals to Present at the Morgan Stanley 16th Annual Global Healthcare Conference on September 13, 2018

SAN DIEGO—(BUSINESS WIRE)—Sep. 4, 2018—ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical companyfocused on the development and commercialization of innovative medicinesthat address unmet medical needs in central nervous system disorders,today announced that it will present at the Morgan Stanley 16^thAnnual Global Healthcare Conference on Thursday, September 13, 2018, at10:35 a.m. Eastern Time in New York City.

A live webcast of ACADIA’s presentation will be accessible on thecompany’s website, www.acadia-pharm.com,under the investors section and an archived recording will be availableon the website through September 27, 2018.

About ACADIA Pharmaceuticals
ACADIA is a biopharmaceuticalcompany focused on the development and commercialization of innovativemedicines to address unmet medical needs in central nervous systemdisorders. ACADIA has developed and is commercializing the first andonly medicine approved for the treatment of hallucinations and delusionsassociated with Parkinson’s disease psychosis. In addition, ACADIA hasongoing clinical development efforts in additional areas withsignificant unmet need including dementia-related psychosis,schizophrenia inadequate response, schizophrenia-negative symptoms,major depressive disorder and Rett syndrome. This press release andfurther information about ACADIA can be found at: www.acadia-pharm.com.

Forward-Looking Statements
Statements in this press releasethat are not strictly historical in nature are forward-lookingstatements. These statements include but are not limited to statementsregarding the timing of future events. These statements are onlypredictions based on current information and expectations and involve anumber of risks and uncertainties. Actual events or results may differmaterially from those projected in any of such statements due to variousfactors, including the risks and uncertainties inherent in drugdiscovery, development, approval and commercialization. For a discussionof these and other factors, please refer to ACADIA’s annual report onForm 10-K for the year ended December 31, 2017 as well as ACADIA’ssubsequent filings with the Securities and Exchange Commission. You arecautioned not to place undue reliance on these forward-lookingstatements, which speak only as of the date hereof. This caution is madeunder the safe harbor provisions of the Private Securities LitigationReform Act of 1995. All forward-looking statements are qualified intheir entirety by this cautionary statement and ACADIA undertakes noobligation to revise or update this press release to reflect events orcircumstances after the date hereof, except as required by law.

Source: ACADIA Pharmaceuticals Inc.

Investor:
ACADIA Pharmaceuticals Inc.
Elena Ridloff,CFA
(858) 558-2871
ir@acadia-pharm.com